Results of both monkey and human trials have highlighted the difficulties in achieving vaccine protection against SIV and HIV. Persistent, recombinant herpesviruses are being used in monkeys to try to match the degree of protection that can be achieved with live attenuated strains of SIV. Results to date have been promising but the absence of anti-Env antibody responses from the recombinant herpesviruses has been a glaring deficiency. The proposed experiments will overcome this deficiency and allow full testing of the promise of this approach.

Public Health Relevance

The proposed experiments will allow a greater appreciation of the potential for recombinant herpesviruses in particular, and persistent vectors in general, for their capacity to provide protection against AIDS virus exposure. If shown to be significantly better than other vaccine approaches, it will shape the emphasis for ongoing preclinical vaccine discovery research.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Method to Extend Research in Time (MERIT) Award (R37)
Project #
Application #
Study Section
Special Emphasis Panel (NSS)
Program Officer
Pensiero, Michael N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Miami School of Medicine
Schools of Medicine
Coral Gables
United States
Zip Code
Großkopf, Anna K; Ensser, Armin; Neipel, Frank et al. (2018) A conserved Eph family receptor-binding motif on the gH/gL complex of Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus. PLoS Pathog 14:e1006912
Shin, Young C; Bischof, Georg F; Lauer, William A et al. (2018) A recombinant herpesviral vector containing a near-full-length SIVmac239 genome produces SIV particles and elicits immune responses to all nine SIV gene products. PLoS Pathog 14:e1007143
Martins, Mauricio A; Tully, Damien C; Pedreño-Lopez, Núria et al. (2018) Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication. J Virol 92:
Bischof, Georg F; Magnani, Diogo M; Ricciardi, Michael et al. (2017) Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys. J Virol 91:
Bischof, G F; Shin, Y C; Fuchs, S P et al. (2017) Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys. Gene Ther 24:487-492
Martins, Mauricio A; Tully, Damien C; Shin, Young C et al. (2017) Rare Control of SIVmac239 Infection in a Vaccinated Rhesus Macaque. AIDS Res Hum Retroviruses 33:843-858
Martins, Mauricio A; Shin, Young C; Gonzalez-Nieto, Lucas et al. (2017) Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques. PLoS Pathog 13:e1006529
Shin, Young C; Bischof, Georg F; Lauer, William A et al. (2015) Importance of codon usage for the temporal regulation of viral gene expression. Proc Natl Acad Sci U S A 112:14030-5
Hahn, Alexander S; Desrosiers, Ronald C (2014) Binding of the Kaposi's sarcoma-associated herpesvirus to the ephrin binding surface of the EphA2 receptor and its inhibition by a small molecule. J Virol 88:8724-34
Hahn, Alexander S; Desrosiers, Ronald C (2013) Rhesus monkey rhadinovirus uses eph family receptors for entry into B cells and endothelial cells but not fibroblasts. PLoS Pathog 9:e1003360

Showing the most recent 10 out of 13 publications